Navigation Links
Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp.

HULL, England and FT. SASKATCHEWAN, Canada, Dec. 22 /PRNewswire-FirstCall/ -- The Advanced Wound Management division of Smith & Nephew plc (LSE: SN; NYSE: SNN), announced today that its affiliates have completed the acquisition of substantially all of the assets of Nucryst Pharmaceuticals Corp. ("Nucryst") (Nasdaq: NCST; TSX: NCS). The acquisition includes the manufacturing assets from Nucryst's Fort Saskatchewan, Canada operations and the intellectual property estate.

Since 2001, Smith & Nephew has held exclusive license for the sale of the ACTICOAT(TM) dressing portfolio, manufactured at the Ft. Saskatchewan site. This acquisition gives Advanced Wound Management full control over all the intellectual property rights, manufacturing and assets relating to the nanocrystalline silver technology that is incorporated in ACTICOAT, which is the second largest brand in the Smith & Nephew Advanced Wound Management product portfolio.

"The ACTICOAT dressings are the only products on the market using the proprietary antimicrobial nanocrystalline silver technology known as SILCRYST(TM). Acquiring this technology and the manufacturing capabilities behind it underlines our commitment to bring clinicians and patients the most advanced solutions for their wound care needs," said Roger Teasdale, President, Advanced Wound Management.


    Liz Hewitt                                       Tel: +44 (0) 20 7401 7646
    Smith & Nephew
    Group Director Corporate Affairs

    Phil Cowdy                                       Tel: +44 (0) 20 7401 7646
    Smith & Nephew
    Director - Investor Relations

    Other Inquiries
    Roger Teasdale                                   Tel: +44 (0) 14 8267 3905
    President, Advanced Wound Management

    Jon Coles                                        Tel: +44 (0) 20 7404 5959
    Brunswick - London

    Katie Cralle                                     Tel: +1 (212) 333 3810
    Brunswick - New York

About Us

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were nearly $3.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

SOURCE Smith & Nephew plc

SOURCE Smith & Nephew plc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment
2. Federal Judge Rejects GlaxoSmithKlines Claims of Privilege
3. Upsher-Smith Announces Milestone in Development of CNS Strategy
4. Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
5. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
6. Arcadia Resources Names Stephen Goldsmith to Board of Directors
7. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
8. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
9. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
10. GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)
11. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... Santa Rosa, CA (PRWEB) , ... November 27, 2015 , ... ... Northern California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine ... dinner meeting. They observed that both STEMI and Sepsis conditions present in similar ways ...
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
(Date:11/26/2015)... Mass. (PRWEB) , ... November 26, 2015 , ... ... thorough second medical opinion process, participated in the 61st annual Employee Benefits Conference. ... Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. The ...
Breaking Medicine News(10 mins):